Takeda Launches New Subsidiary in Peru - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda Launches New Subsidiary in Peru



Takeda Pharmaceuticals International GmbH has expanded its presence in Latin America with the addition of a wholly-owned subsidiary in Peru. Takeda Peru will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Takeda has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia, Ecuador and now Peru. According to IMS Market Prognosis, pharmaceutical sales in those countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017.

It is estimated that Peru’s GDP totaled $200 billion in 2012 while pharmaceutical sales amounted to $1.5 billion and are expected to continue to grow by 8% during 2013*.

Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the organization from Takeda Colombia, where he headed the Takeda Sales and Marketing organization following the acquisition of Farmacol Laboratories.

Source: Takeda Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here